1
|
Chin W, Steeneveld W, Nielen M, Christensen J, Klaas IC, Lam TJGM. The association between time-series milk β-hydroxybutyrate dynamics and early reproductive performance of dairy cows. J Dairy Sci 2024:S0022-0302(24)00629-5. [PMID: 38554827 DOI: 10.3168/jds.2023-24184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 02/22/2024] [Indexed: 04/02/2024]
Abstract
The DeLaval Herd Navigator is an on-farm sensor system that measures on a frequent basis milk progesterone (P4) and β-hydroxybutyrate (BHB) in individual cows to closely monitor reproductive performance and energy balance. This information provides the opportunity to investigate the dynamics of BHB measured in milk (mBHB) and study the association between mBHB and early reproductive performance. The objectives of the study were (1) to describe mBHB dynamics within the first 20 d in milk (DIM), and (2) to evaluate the association between mBHB dynamics and early reproductive performance at cow-level. Two-year time-series data from 4,133 dairy cows in 38 Dutch dairy farms were available for analysis. Data included information on mBHB, daily milk yield and the indicators of early reproductive performance, days from calving to resumption of cyclicity, days from calving to first estrus, and days from calving to first insemination. The following mBHB dynamic parameters were defined based on the first 20 DIM for each individual cow: average mBHB (AvgBHB), DIM when mBHB was for the first time ≥80 μmol/L (OnsetKeto), the total number of consecutive days a cow had mBHB concentration ≥80 μmol/L, and the number of measurements mBHB concentration was ≥80 μmol/L. Three Cox proportional hazard regression models with random herd effect were developed to evaluate the association between cow level mBHB dynamics and days from calving to resumption of cyclicity, first estrus, and first insemination. Results showed that the mean AvgBHB within 20 DIM among all cows was 73 μmol/L. The mean OnsetKeto within 20 DIM, was 8 DIM. Among all cows having hyperketolactia, 55.8% (1,350/2,419) had OnsetKeto in the first week of lactation. In total, 41.5% (1,714/4,133) of the cows did not have OnsetKeto in the first 20 DIM. An early onset of hyperketolactia was associated with delayed fertility events. Cows with higher AvgBHB have a prolonged time interval from calving to resumption of cyclicity and first estrus. Information on mBHB dynamics and the association with early reproductive performance provides insights that might be helpful to improve reproductive performance of individual dairy cows.
Collapse
Affiliation(s)
- W Chin
- Department Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 7, 3508 TD Utrecht, the Netherlands
| | - W Steeneveld
- Department Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 7, 3508 TD Utrecht, the Netherlands.
| | - M Nielen
- Department Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 7, 3508 TD Utrecht, the Netherlands
| | - J Christensen
- Lattec I/S, Slangerupgade 69, 3400 Hillerod, Denmark
| | - I C Klaas
- DeLaval International AB, 14721 Tumba, Sweden
| | - T J G M Lam
- Department Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 7, 3508 TD Utrecht, the Netherlands
| |
Collapse
|
2
|
Bhowmick M, Christensen J, Adjorlolo R, Ullrich B. Photoluminescence from Two-Phase Nanocomposites Embedded in Polymers. Micromachines (Basel) 2024; 15:111. [PMID: 38258230 PMCID: PMC10820105 DOI: 10.3390/mi15010111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2023] [Revised: 01/01/2024] [Accepted: 01/05/2024] [Indexed: 01/24/2024]
Abstract
A set of polymer-embedded, two-colored nanocomposites were prepared where the co-existing emission peaks (~578 nm and ~650 nm) had different ratios at their emission thresholds. The nanocomposite samples were simultaneously excited by a 405 nm laser, and the growth of photoluminescence intensities was studied as a function of excitation intensity. The two peaks showed different growth evolution mechanisms. The factors impacting this difference could be (1) energy transfer between the two sized nanoparticles; (2) relaxation mechanism of smaller nanoparticles; and (3) material properties of the polymer.
Collapse
Affiliation(s)
- Mithun Bhowmick
- Mathematical and Physical Sciences, Miami University Regionals, Middletown, OH 45042, USA
| | - James Christensen
- Construction Engineering Research Laboratory, United States Army Corps of Engineers, Champaign, IL 61822, USA
| | - Richard Adjorlolo
- Mathematical and Physical Sciences, Miami University Regionals, Middletown, OH 45042, USA
| | | |
Collapse
|
3
|
Daniel SB, Wiesen C, Christensen J, Frazier-Bowers SA. Using a digital platform to establish odontometric variation based on race, gender and Angle classification. Orthod Craniofac Res 2023; 26 Suppl 1:204-209. [PMID: 37073633 DOI: 10.1111/ocr.12664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Revised: 03/23/2023] [Accepted: 04/01/2023] [Indexed: 04/20/2023]
Abstract
Orthodontists often encounter significant clinical challenges in the finishing stages of treatment due to a disproportion in interarch tooth size relationships. Despite the increasing presence of digital technology and concomitant focus on customized treatment approaches, there is a gap in the knowledge of how generating tooth size data using digital versus traditional methods may impact our treatment regime. OBJECTIVE This study aimed to compare the prevalence of tooth size discrepancies using digital models and a digitally based cast analysis in our cohort based on (i) Angle's Classification; (ii) gender and (iii) race. MATERIALS AND METHODS The mesiodistal widths of teeth in 101 digital models were assessed using computerized odontometric software. A Chi-square test was used to determine the prevalence of tooth size disproportions among the study groups. The differences between all three groups of the cohort were analysed using a three-way analysis of variance (ANOVA). RESULTS An overall Bolton tooth size discrepancy (TSD) prevalence of 36.6% was observed in our study cohort; 26.7% had an anterior Bolton TSD. No differences existed in the prevalence of tooth size discrepancies between male and female subjects as well as between the different malocclusion groups (P > .05). Caucasian subjects had a statistically significant smaller prevalence of TSD compared to Black and Hispanic patients (P < .05). CONCLUSION The prevalence results in this study illuminate how relatively common TSD is and underscores the importance of proper diagnosis. Our findings also suggest that racial background may be an influential factor in the presence of TSD.
Collapse
Affiliation(s)
- S B Daniel
- Orthodontics Program, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - C Wiesen
- Odum Institute for Research in Social Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - J Christensen
- Department of Pediatric Dentistry, and Private Practice in Pediatric Dentistry and Orthodontics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - S A Frazier-Bowers
- Department of Orthodontics and Oral Facial Genetics, Indiana University School of Dentistry, Indianapolis, Indiana, USA
| |
Collapse
|
4
|
Behrendt P, Berninger MT, Thürig G, Dehoust J, Christensen J, Frosch KH, Krause M, Hartel MJ. Nanoscopy and an extended lateral approach can improve the management of latero-central segments in tibial plateau fractures: a cadaveric study. Eur J Trauma Emerg Surg 2022; 49:1433-1439. [DOI: 10.1007/s00068-022-02188-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 11/24/2022] [Indexed: 12/13/2022]
Abstract
Abstract
Introduction
The objective of this investigation was to compare different techniques to improve visualization and reduction in tibial plateau fractures involving the central lateral segments.
Methods
Matched pairs of pre-fractured cadaveric tibial plateau fractures that include the central lateral segments were treated by either an anterolateral approach (supine) or PL approach (prone). Reduction was stepwise extended by additional fracturoscopy (FS), nanoscopy (NS) and lastly by epicondyle osteotomy (ECO). Reduction was analyzed by 3D scan and visualization of the lateral plateau was quantified.
Results
Ten specimens (3 pairs 41B3.1, 2 pairs 41C3.3) were analyzed. Fracture steps involving the antero-latero-central (ALC) segment were insufficiently reduced after fluoroscopy using both approaches (AL 2.2 ± 1.2 mm vs PL 2.2 ± 1.0 mm, p 0.95). Additional NS and ECO achieved optimized fracture reduction in the ALC segment (NS AL 1.6 ± 1.3 mm vs PL 0.8 ± 0.9 mm, p 0.32). NS provided visualization of the entire lateral plateau (PL 102.9% ± 7.4, AL 108.8 ± 19.2%), while fracturoscopy only allowed visualization of the ALL segment and partially of PLL and ALC segments (PL 22.0 ± 23.4%, AL 29.7 ± 18.3%).
Conclusion
Optimized reduction of tibial head fractures with involvement of latero-central segments requires additional video-assisted reduction or extended approaches. Nanoscopy helps visualizing of the entire lateral plateau, when compared to fracturoscopy and may become a valuable reduction aid.
Collapse
|
5
|
Lasgaard M, Løvschall C, Qualter P, Laustsen LM, Lim MH, Maindal HT, Hargaard AS, Christensen J. Are loneliness interventions effective in reducing loneliness? A meta-analytic review of 128 studies. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac129.266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Loneliness is widely acknowledged as a growing public health concern, accelerated by the onset of the COVID-19 pandemic. However, our knowledge about the effectiveness of interventions to reduce loneliness across the lifespan, including knowledge of different intervention strategies, is limited. This preregistered systematic review and meta-analysis aimed to evaluate the effect of interventions to reduce loneliness. The systematic review identified 136 studies. The meta-analysis included 128 studies comprising 54 randomised controlled trials (RCTs) (n = 6,379), 23 multi-cohort studies (n = 2,882) and 48 single-cohort studies (n = 3,009). A small to moderate statistically significant effect was detected (RCTs; SMD = -0.47, multi-cohort studies; SMD = -0.24, single cohort-studies; SMD = -0.42). Using the GRADE system, confidence in the estimates was assessed as low or very low, implying that the estimates may potentially be higher or lower. No statistically significant differences were found between age groups. Psychological treatment, social support interventions, and social and emotional skills training appeared to be the most effective intervention strategies in reducing loneliness but there is currently no strong reason to prefer one intervention strategy over another. Further analyses demonstrated that the long-term effects (i.e., one to six months after the intervention) were comparable to the short-term effects (i.e., up to four weeks after the intervention). Findings from the current meta-analyses provide overall evidence of the effectiveness of loneliness interventions. Given methodological limitations, including the heterogeneity of the reviewed studies, it remains unclear who the interventions would help the most. Overall, there is a need for rigorous and high-quality development and evaluations of interventions for loneliness.
Key messages
• The findings of this meta-analytic review suggest that interventions designed to reduce loneliness are effective.
• Psychological treatment, social support interventions, and social and emotional skills training are the most promising interventions, albeit the magnitude of the effects is moderate.
Collapse
Affiliation(s)
- M Lasgaard
- Public Health and Health Services Research, Defactum, Central Denmark Region , Aarhus, Denmark
| | - C Løvschall
- Public Health and Health Services Research, Defactum, Central Denmark Region , Aarhus, Denmark
| | - P Qualter
- Manchester Institute of Education, University of Manchester , Manchester, UK
| | - LM Laustsen
- Public Health and Health Services Research, Defactum, Central Denmark Region , Aarhus, Denmark
- Department of Clinical Epidemiology, Aarhus University, Aarhus University Hospital , Aarhus, Denmark
| | - MH Lim
- Iverson Health Innovation Research Institute, Swinburne University of Technology , Melbourne, Australia
| | - HT Maindal
- Department of Public Health, Aarhus University , Aarhus, Denmark
| | - AS Hargaard
- Public Health and Health Services Research, Defactum, Central Denmark Region , Aarhus, Denmark
| | - J Christensen
- Public Health and Health Services Research, Defactum, Central Denmark Region , Aarhus, Denmark
- Department of Psychology, University of Southern Denmark , Odense, Denmark
| |
Collapse
|
6
|
Christensen J, Pedersen SS, Andersen CM, Qualter P, Lund R, Lasgaard M. The association of loneliness and social isolation with healthcare utilization in Denmark. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac130.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Objectives
The present prospective cohort study investigated the association of loneliness and social isolation (SI) with healthcare utilization (HCU) in the general population over time.
Methods
Data from the 2013 Danish “How are you?’ survey (n = 29,472) were combined with individual-level register data from the National Danish Patient Registry and the Danish National Health Service Registry over a 6-year follow-up period (2013-2018). Negative binomial regression analyses were performed while adjusting for baseline demographics and chronic disease.
Results
Loneliness measured at baseline was significantly associated with more GP contacts (incident-rate ratio (IRR) = 1.03, 95% confidence interval (CI) [1.02, 1.04]), more emergency treatments (IRR = 1.06, 95% CI [1.03, 1.10]), more emergency admissions (IRR = 1.06, 95% CI [1.03, 1.06]), and hospital admission days (IRR=1.05, 95% CI [1.00, 1.11]) across the 6-year follow-up period. No significant associations were found between social isolation and HCU with one minor exception, in which SI was associated with fewer planned outpatient treatments (IRR = .97, 95% CI [.94, .99]).
Conclusions
Our findings suggest that loneliness is a risk factor for certain types of HCU, independent of social isolation, baseline demographics, and chronic disease.
Key messages
Collapse
Affiliation(s)
- J Christensen
- Department of Psychology, University of Southern Denmark , Odense, Denmark
- Public Health and Health Services Research, Defactum, Central Denmark Region , Aarhus, Denmark
| | - SS Pedersen
- Department of Psychology, University of Southern Denmark , Odense, Denmark
- Department of Cardiology, Odense University Hospital , Odense, Denmark
| | - CM Andersen
- Department of Psychology, University of Southern Denmark , Odense, Denmark
- Steno Diabetes Center Odense, Odense University Hospital , Odense, Denmark
| | - P Qualter
- Manchester Institute of Education, University of Manchester , Manchester, UK
| | - R Lund
- Department of Public Health, University of Copenhagen , Copenhagen, Denmark
- Center for Healthy Aging, University of Copenhagen , Copenhagen, Denmark
| | - M Lasgaard
- Public Health and Health Services Research, Defactum, Central Denmark Region , Aarhus, Denmark
| |
Collapse
|
7
|
Wetterslev M, Georgiadis S, Christiansen SN, Pedersen SJ, Sørensen IJ, Hetland ML, Duer A, Boesen M, Gosvig KK, Møllenbach Møller J, Bakkegaard M, Brahe CH, Steen Krogh N, Jensen B, Madsen O, Christensen J, Hansen A, Noerregaard J, Røgind H, Østergaard M. POS0298 OCCURRENCE AND PREDICTION OF FLARE AFTER TAPERING OF TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPatients with axial spondyloarthritis (axSpA) in clinical remission tapered Tumor Necrosis Factor inhibitor (TNFi) therapy according to a clinical guideline and had 2 years´ follow-up [1].ObjectivesWe aimed to investigate flare frequency, dose at which flare occurred, type of flare (clinical/ Bath ankylosing spondylitis disease activity index (BASDAI)/magnetic resonance imaging (MRI)) and predictors of flare.MethodsPatients in clinical remission (BASDAI<40, physician global score<40 and without disease activity the previous year) tapered TNFi to 2/3 standard dose at baseline, 1/2 at week (w)16, 1/3 at w32 and 0 (discontinuation) at w48. Patients who flared were increased to previous dose. Predictors of flare at each dose step were investigated by regression analyses.ResultsOf 108 patients, 106 (99%) flared before year 2 (flare occurring mean (SD) 99(44.3) days after last tapering). Twenty-nine patients (27%) flared at 2/3 standard dose, 21 (20%) at 1/2 dose, 29 (27%) at 1/3 dose and 27 (25%) after discontinuation. One-hundred-and-five (99%) had clinical flare, 25 (24%) BASDAI flare and 23 (29% of patients with MRI at flare) MRI flare; and forty-one patients (41%) fulfilled the ASAS-definition of clinically important worsening (≥0.9 increase since baseline) (Figure 1). Most common flare symptoms were back/buttock pain (n=93 (89%)) and pain in peripheral joints/entheseal regions (n=48 (46%)). Higher baseline physician global score was an independent predictor of flare after tapering to 2/3 (Odds ratio=1.19 (95% Confidence Interval=1.05-1.41); p=0.011) (Table 1). Changes in clinical and/or imaging variables in the 16 weeks prior to tapering did not predict flare (data not shown).Table 1.Prediction of flare within 16 weeks after tapering to 2/3 dose (n=74)Values are from timepoint of tapering from full dose to 2/3 doseUnivariate analysesFinal multivariable analyses*OR(95% CI)p-valueOR(95% CI)p-valueMale gender0.96(0.25 - 4.14)0.955Age1.00(0.96 - 1.04)0.880Time since diagnosis1.00(0.95 - 1.06)0.863Current smoker0.70(0.20 - 2.20)0.543HLA-B27 positive0.66(0.18 - 2.41)0.515Previous bDMARDs1.28(0.66 - 2.49)0.458Patient pain VAS1.02(0.98 - 1.06)0.310Physician global VAS1.19(1.04 - 1.41)0.0121.19(1.04 - 1.41)0.011ASDAS1.66(0.70 - 4.10)0.251mNYc positive0.78(0.29 - 2.09)0.615SPARCC SIJ Inflammation Index1.01(0.90 - 1.12)0.861CANDEN Total inflammation0.95(0.65 - 1.25)0.702SPARCC SSS Erosion1.11(0.91 - 1.37)0.293CANDEN Fat0.99(0.96 - 1.02)0.705AUC (95% CI)0.66 (0.54 - 0.78)Predictors were selected by applying backward selection in stacked data. p-values by likelihood ratio tests. Bold indicates p-values<0.1 in univariate analyses. Predictors were selected by backward selection in stacked imputed datasets after applying a fixed weight to all observations, accounting for the average fraction of missing data across all variables under consideration. *Results were derived in non-imputed data (no missing values in selected predictors). CIs given as profile likelihood CIs. AUC estimated based on internal validation by bootstrapping with 1000 samples.ASDAS, Ankylosing Spondylitis Disease Activity Score; bDMARDs, biological disease modifying anti-rheumatic drugs; AUC, Area Under the receiver operating characteristic Curve; CANDEN, Canada-Denmark MRI scoring system of the spine in patients with axial spondyloarthritis; CI, confidence interval; mNYc, modified New York criteria; SIJ, sacroiliac joint; SPARCC SIJ inflammation, Spondyloarthritis Research Consortium of Canada Sacroiliac joint inflammation; SPARCC SSS, Spondyloarthritis Research Consortium of Canada Sacroiliac joint Structural Score; VAS, visual analogue scale.ConclusionAlmost all (99%) axSpA patients in clinical remission flared during tapering to discontinuation, but above half not before receiving 1/3 dose or less. Higher physician global score was the only independent predictor of flare.References[1]Wetterslev M, et al. Rheumatology (Oxford) 2021;10.1093/rheumatology/keab755.Disclosure of InterestsMarie Wetterslev: None declared, Stylianos Georgiadis: None declared, Sara Nysom Christiansen Speakers bureau: BMS and GE, Grant/research support from: Novartis, Susanne Juhl Pedersen Speakers bureau: MSD, Pfizer, AbbVie, Novartis and UCB, Consultant of: AbbVie and Novartis, Grant/research support from: AbbVie, MSD, and Novartis, Inge Juul Sørensen: None declared, Merete Lund Hetland Consultant of: MSD, Biogen, Pfizer, Eli Lilly, Orion Pharma, CellTrion, Samsung Bioepis, and Janssen Biologics BV, Grant/research support from: MSD, Biogen, Pfizer, Bristol-Myers Squibb, AbbVie, Roche and Novartis, Anne Duer: None declared, Mikael Boesen Speakers bureau: Image Analysis Group, Esaote, AbbVie, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer, UCB, Novo, GSK, Takeda, Geurbet, Biogen, Radiobotics and Chondrometrics, Consultant of: Image Analysis Group, Esaote, AbbVie, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer, UCB, Novo, GSK, Takeda, Geurbet, Biogen, Radiobotics and Chondrometrics, Grant/research support from: Image Analysis Group, Esaote, AbbVie, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer, UCB, Novo, GSK, Takeda, Geurbet, Biogen, Radiobotics and Chondrometrics, Kasper K Gosvig: None declared, Jakob Møllenbach Møller: None declared, Mads Bakkegaard: None declared, Cecilie Heegaard Brahe: None declared, Niels Steen Krogh: None declared, Bente Jensen: None declared, Ole Madsen: None declared, Jan Christensen: None declared, Annette Hansen Speakers bureau: speaker fees from Elly Lilly, Jesper Noerregaard: None declared, Henrik Røgind: None declared, Mikkel Østergaard Speakers bureau: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Consultant of: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Grant/research support from: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB
Collapse
|
8
|
Rainer L, Granbichler C, Kobulashvili T, Kuchukhidze G, Rauscher C, Renz N, Langthaler P, Braun M, Linehan C, Christensen J, Siebert U, Trinka E. Prevalence of Comorbidities, and Affective Disorders in Epilepsy: A Latent Class Analysis Approach. Epilepsy Res 2022; 182:106917. [DOI: 10.1016/j.eplepsyres.2022.106917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/27/2022] [Accepted: 03/27/2022] [Indexed: 11/03/2022]
|
9
|
Harder CB, Persson S, Christensen J, Ljubic A, Nielsen EM, Hoorfar J. Molecular diagnostics of Salmonella and Campylobacter in human/animal fecal samples remain feasible after long-term sample storage without specific requirements. AIMS Microbiol 2022; 7:399-414. [PMID: 35071939 PMCID: PMC8712530 DOI: 10.3934/microbiol.2021024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Accepted: 09/05/2021] [Indexed: 11/27/2022] Open
Abstract
Rapid advances in the development of sequencing technologies, numbers of commercial providers and diminishing costs have made DNA-based identification and diagnostics increasingly accessible to doctors and laboratories, eliminating the need for local investments in expensive technology and training or hiring of skilled technicians. However, reliable and comparable molecular analyses of bacteria in stool samples are dependent on storage and workflow conditions that do not introduce post-sampling bias, the most important factor being the need to keep the DNA at a stable detectable level. For that reason, there may remain other prohibitively costly requirements for cooling or freezing equipment or special chemical additives. This study investigates the diagnostic detectability of Salmonella and Campylobacter DNA in human, pig and chicken stool samples, stored at different temperatures and with different preservation methods. Stool samples were spiked with 106 CFU/mL of both Salmonella and Campylobacter strains stored at −20 °C, 5 °C and 20 °C (Room temperature, RT) and treated with either RNAlater, EDTA or Silica/ethanol. DNA was extracted at 9 different time points within 30 days and quantified by Qubit (total DNA) and qPCR (Salmonella and Campylobacter DNA). We found no statistically significant differences among the different preservation methods, and DNA from both species was easily detected at all time points and at all temperatures, both with and without preservation. This suggests that infections by these bacteria can be diagnosed and possibly also analysed in further detail simply by taking a stool sample in any suitable sealed container that can be transported to laboratory analysis without special storage or preservation requirements. We briefly discuss how this finding can benefit infection control in both developed and developing countries.
Collapse
Affiliation(s)
- C B Harder
- Statens Serum institut, Dept. Bacteriology, Parasitology and Fungi, Artillerivej 5, 2300 Copenhagen, Denmark.,Molecular Ecology, Microbial Ecology and Evolutionary Genetics, Lund University, Sölvegatan 37, 223 62 Lund
| | - S Persson
- Statens Serum institut, Dept. Bacteriology, Parasitology and Fungi, Artillerivej 5, 2300 Copenhagen, Denmark
| | - J Christensen
- Danish Veterinary and Food Administration, Microbiological department, Søndervang 4, 4100 Ringsted
| | - A Ljubic
- AGC Biologics, Process Transfer, Vandtårnsvej 83, 2860 Søborg, Denmark
| | - E M Nielsen
- Statens Serum institut, Dept. Bacteriology, Parasitology and Fungi, Artillerivej 5, 2300 Copenhagen, Denmark
| | - J Hoorfar
- Technical University of Denmark, National Food Institute, 2800 Kgs. Lyngby, Denmark
| |
Collapse
|
10
|
Horsbøl TA, Dalton SO, Christensen J, Petersen AC, Azawi N, Donskov F, Holm ML, Nørgaard M, Lund L. Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study. Acta Oncol 2022; 61:58-63. [PMID: 34807805 DOI: 10.1080/0284186x.2021.2005255] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
BACKGROUND Presence of comorbid diseases at time of cancer diagnosis may affect prognosis. We evaluated the impact of comorbidity on survival of patients diagnosed with renal cell carcinoma (RCC), overall and among younger (<70 years) and older (≥70 years) patients. METHODS We established a nationwide register-based cohort of 7894 patients aged ≥18 years diagnosed with RCC in Denmark between 2006 and 2017. We computed 1- and 5-year overall survival and hazard ratios (HRs) for death according to the Charlson Comorbidity Index (CCI) score. RESULTS Survival decreased with increasing CCI score despite an overall increase in survival over time. The 5-year survival rate of patients with no comorbidity increased from 57% among those diagnosed in 2006-2008 to 69% among those diagnosed in 2012-2014. During the same periods, the survival rate increased from 46% to 62% among patients with a CCI score of 1-2 and from 39% to 44% for those with a CCI score of ≥3. Patients with CCI scores of 1-2 and ≥3 had higher mortality rates than patients with no registered comorbidity (HR 1.15, 95% CI 1.06-1.24 and HR 1.56, 95% CI 1.40-1.73). Patterns were similar for older and younger patients. Particularly, diagnoses of liver disease (HR 2.09, 95% CI 1.53-2.84 and HR 4.01, 95% CI 2.44-6.56) and dementia (HR 2.16, 95% CI 1.34-3.48) increased mortality. CONCLUSION Comorbidity decreased the survival of patients with RCC, irrespective of age, despite an overall increasing survival over time. These results highlight the importance of focusing on comorbidity in this group of patients.
Collapse
Affiliation(s)
- T. A. Horsbøl
- Survivorship & Inequality in Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
- National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark
| | - S. O. Dalton
- Survivorship & Inequality in Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark
- Danish Research Center for Equality in Cancer (COMPAS), Department for Clinical Oncology & Palliative Care, Zealand University Hospital, Naestved, Denmark
- Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - J. Christensen
- Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - A. C. Petersen
- Department of Pathology, Aalborg University Hospital, Aalborg, Denmark
| | - N. Azawi
- Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- Department of Urology, Zealand University hospital, Roskilde, Denmark
| | - F. Donskov
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - M. L. Holm
- Department of Urology, Rigshospitalet, Copenhagen, Denmark
| | - M. Nørgaard
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - L. Lund
- Department of Urology, Odense University Hospital, Odense, Denmark
- Department of Clinical Research, University of Southern Denmark, Academy of Geriatric Cancer Research (AgeCare), Odense, Denmark
| |
Collapse
|
11
|
Ackerson B, Sperduto W, Oyekunle T, Niedzwiecki D, Christensen J, Kelsey C. Interpreting Post-SBRT Lung Imaging: A Comparison of Radiology and Radiation Oncology Impressions. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Li S, Tang K, Khodadadi-Jamayran A, Jen J, Han H, Guidry K, Chen T, Hao Y, Fedele C, Zebala J, Maeda D, Christensen J, Olson P, Athanas A, Wong K, Neel B. OA12.03 Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Tabernero J, Bendell J, Corcoran R, Kopetz S, Lee J, Davis M, Christensen J, Chi A, Kheoh T, Yaeger R. P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
14
|
Soussi BG, Cordtz RL, Kristensen S, Bork CS, Christensen J, Schmidt EB, Prieto-Alhambra D, Dreyer L. POS0025 INCIDENCE RATES AND POINT PREVALENCE OF SEROPOSITIVE AND SERONEGATIVE RHEUMATOID ARTHRITIS IN DENMARK: A NATIONWIDE REGISTER-BASED STUDY FROM 1998 TO 2018 USING FOUR DIFFERENT CASE CRITERIA. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Few previous studies have investigated the incidence rate (IR) and point prevalence (PP) of seropositive and seronegative rheumatoid arthritis (RA), and further, the estimates remain unknown in the Danish population.Objectives:To investigate the IR and PP of seropositive and seronegative RA in the adult Danish population from 1998 to 2018 using four register-based case definitions of RA.Methods:Nationwide register-based cohort study. Using the Danish administrative registers, patients with RA between 1998 and end of 2018 were identified. ICD-10 codes for RA were identified in the Danish National Patient Registry and information on DMARD prescriptions were obtained through the Danish National Prescription Registry using ATC codes. The used case definitions were1: Criteria A, first time M05/M06 RA diagnosis and redemption of a DMARD in the following year; Criteria B, two RA diagnoses within 90 days of each other, originating from department of rheumatology or general internal medicine, where the latest registered M05/M06 diagnosis defined the serologic status; Criteria C, a M05/M06 diagnosis recorded at any time preceded or followed by redemption of a DMARD prescription within one year, where the M05/M06 diagnosis recorded determined the serologic status; Criteria D, as Criteria A, but with the additional requirements that cases had no registration for other selected inflammatory diseases.In calculation of IRs the total Danish population from 1998 to 2018 was used as reference population for standardisation. The PP was calculated for years 2000, 2009, 2011 and 2018.Results:From 1998 to 2018 the overall IR was 18.0 (95%CI 17.7 to 18.3) per 100,000 person years (PY) for seropositive RA and 16.7 (95%CI 16.4 to 16.9) per 100,000 PY for seronegative RA using Criteria A. A higher IR for seropositive RA than for seronegative RA was found regardless of the case criteria used. Figure 1 shows the temporal IRs of seropositive and seronegative RA.Regardless of case criteria used, the PP increased from 2000 to 2018 for both seropositive and seronegative RA, and the estimates were higher for seropositive RA than for seronegative RA (Table 1).Table 1.Point prevalence of rheumatoid arthritis in Denmark in year 2000, 2009, 2011 and 2018 using four different case definitions2000200920112018SeropositiveSeronegativeSeropositiveSeronegativeSeropositiveSeronegativeSeropositiveSeronegativeCriteria AN3029274174747127871281211243711662Population3964040416629842028914269677PP, % (95%CI)0.08 (0.08 to 0.08)0.07 (0.07 to 0.07)0.18 (0.18 to 0.19)0.17 (0.17 to 0.18)0.21 (0.20 to 0.21)0.19 (0.19 to 0.20)0.27 (0.27 to 0.28)0.26 (0.25 to 0.26)Criteria BN7507489311565903312710100111633413340PP, % (95%CI)0.20 (0.19 to 0.20)0.13 (0.12 to 0.13)0.28 (0.28 to 0.29)0.22 (0.21 to 0.22)0.30 (0.30 to 0.31)0.24 (0.23 to 0.24)0.36 (0.35 to 0.36)0.29 (0.29 to 0.30)Criteria CN6701457011174912512417101491588113712PP, % (95%CI)0.18 (0.17 to 0.18)0.12 (0.12 to 0.12)0.27 (0.27 to 0.28)0.22 (0.22 to 0.23)0.29 (0.29 to 0.30)0.24 (0.24 to 0.25)0.35 (0.34 to 0.35)0.30 (0.30 to 0.31)Criteria DN272423906612598476956759108309452PP, % (95%CI)0.07 (0.07 to 0.07)0.06 (0.06 to 0.07)0.16 (0.16 to 0.16)0.15 (0.14 to 0.15)0.18 (0.18 to 0.19)0.16 (0.16 to 0.17)0.24 (0.23 to 0.24)0.21 (0.20 to 0.21)PP = Point prevalenceConclusion:In Denmark, the IR and PP estimates were higher for seropositive compared to seronegative RA during the study period. However, when applying stricter case criteria for RA (Criteria A and D) the differences in IR and PP estimates were smaller, than when using less strict criteria (Criteria B and C). The findings of such small differences between seropositive and seronegative IRs warrant further investigation.References:[1]Soussi BG et al. Incidence and prevalence of rheumatoid arthritis in Denmark: a nationwide population based study investigating the effect of four different case definitions [abstract]. Ann Rheum Dis. 2020;79(supplement 1):46Acknowledgements:The authors will like to thank The Danish Rheumatism Association for supporting this work.Disclosure of Interests:Bolette Gylden Soussi: None declared, René Lindholm Cordtz: None declared, Salome Kristensen: None declared, Christian Sørensen Bork: None declared, Jeppe Christensen: None declared, Erik Berg Schmidt: None declared, Daniel Prieto-Alhambra Grant/research support from: Grants from AMGEN, UCB Biopharma and Les Laboratoires Servier; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA’s department and open for external participants, Lene Dreyer Grant/research support from: Grants from BMS, Galderma and Eli Lilly.
Collapse
|
15
|
Halane HIM, Hargreave M, Kjaer SK, Christensen J, Mørch LS. Maternal use of hormonal contraception and epilepsy in offspring. Hum Reprod 2021; 36:1674-1681. [PMID: 33580954 DOI: 10.1093/humrep/deab023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 01/04/2021] [Indexed: 11/14/2022] Open
Abstract
STUDY QUESTION Is maternal use of hormonal contraception associated with the development of epilepsy in the offspring? SUMMARY ANSWER We found that maternal use of hormonal contraception was associated with a slightly increased risk of epilepsy in the offspring. WHAT IS KNOWN ALREADY Foetal exposure to exogenous hormones has been associated with changes in brain development. However, little is known about maternal hormonal contraception use and development of epilepsy in the offspring. STUDY DESIGN, SIZE, DURATION A nationwide cohort of all live born children born in Denmark between 1 January 1998 and 31 December 2014, was followed from day 29 after birth for epilepsy (first diagnosis of epilepsy or first redeemed prescription for anti-epileptic medication) to censoring (emigration, death) or 31 December 2015, whichever occurred first. PARTICIPANTS/MATERIALS, SETTING, METHODS Diagnoses of epilepsy were obtained from the National Patient Registry. The Danish National Prescription Registry supplied information on redeemed prescriptions for hormonal contraception and anti-epileptic medication. Maternal hormonal contraception use was categorized as never use (reference group), previous use (prescriptions redeemed >3 months before pregnancy start) and recent use (prescriptions redeemed ≤3 months before or during pregnancy). MAIN RESULTS AND THE ROLE OF CHANCE The data show that 17 585 children developed epilepsy during a median follow-up of 9.2 years (9 732 635 person-years). The hazard ratio (HR) for epilepsy was 1.07 (95% CI 1.02-1.13) in children of mothers who had used any type of hormonal contraception recently, compared with children of mothers who had not used hormonal contraception. The HR was similar for recent use of oral combined products, while the HRs for recent or previous use of non-oral combined products were 1.32 (95% CI 0.98-1.77) and 1.16 (95% CI 1.02-1.32), respectively. For non-oral progestin-only products, the HRs were 1.19 (95% CI 1.04-1.38) and 1.53 (95% CI 1.31-1.80), respectively, for recent and previous use. LIMITATIONS, REASONS FOR CAUTION There may be some misclassification of maternal hormonal contraception use, as some women may not have used the redeemed prescriptions or used them at a different point in time; potentially leading to an attenuation of the estimates. In addition, although we were able to account for known risk factors for epilepsy, unknown or residual confounding cannot be ruled out. WIDER IMPLICATIONS OF THE FINDINGS Our findings are based on nationwide population-based data and can therefore be applied to other similar populations. However, as this is the first study in this field, further studies are needed to confirm our findings. STUDY FUNDING/COMPETING INTEREST(S) No specific funding was obtained for this study, which was supported by internal funding at the Unit of Virus, Lifestyle and Genes. All authors report no conflicts of interest. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- H I M Halane
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 2100 Copenhagen O, Denmark
| | - M Hargreave
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 2100 Copenhagen O, Denmark
| | - S K Kjaer
- Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 2100 Copenhagen O, Denmark.,Department of Gynaecology, Rigshospitalet, 2100 Copenhagen O, Denmark
| | - J Christensen
- Department of Clinical Medicine, Aarhus University, 8200 Aarhus N, Denmark.,Department of Neurology, Aarhus University Hospital, 8200 Aarhus N, Denmark
| | - L S Mørch
- Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Society Research Center, 2100 Copenhagen O, Denmark
| |
Collapse
|
16
|
Christensen J, Miliken A, Brown J, Dhillon G. Abdominal Malakoplakia Secondary to Disseminated Mycobacterium Avium Complex after Lung Transplant. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.2066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
17
|
Spira A, Riely G, Lawler W, Shum M, Socinski M, Yanagihara R, Roshan S, Kheoh T, Christensen J, Chao R, Janne P, Garassino M. P90.03 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1286] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Msaouel P, Siefker-Radtke A, Sweis R, Mao S, Rosenberg J, Vaishampayan U, Kalebasty AR, Pili R, Bupathi M, Nordquist L, Shaffer D, Davis N, Zhang T, Gandhi S, Christensen J, Shazer R, Yan X, Winter M, Der-Torossian H, Iyer GV. 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.777] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
19
|
Høeg BL, Johansen C, Christensen J, Frederiksen K, Dalton SO, Bøge P, Dencker A, Dyregrov A, Bidstrup PE. Does losing a parent early influence the education you obtain? A nationwide cohort study in Denmark. J Public Health (Oxf) 2020; 41:296-304. [PMID: 29684221 DOI: 10.1093/pubmed/fdy070] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Revised: 02/06/2018] [Accepted: 04/04/2018] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Health inequalities are rooted in education and we investigate the association between early parental death and attainment across the educational spectrum. METHODS Using total population data on Danes born between 1982 and 2000 (n = 1 043 813), we assess incidence rate ratios (RRs) by gender for attainment of each educational level (basic school, high school or vocational training, bachelor degree or professional programme, and university graduate degree) according to loss of a parent before the age of 18 years. We adjust for family income, education and psychiatric illness and examine parent's gender, cause of death and child's age at time of death as potential moderators. RESULTS Bereaved people had significantly lower attainment rates than non-bereaved people: basic school (RR = 0.95; 95% CI: 0.93-0.97 for men and 0.96; 0.94-0.98 for women), high school or vocational training (0.78; 0.76-0.80 for men and 0.82; 0.80-0.84 for women), bachelor degree or professional programme (0.74; 0.70-0.79 for men and 0.83; 0.79-0.86 for women) and university graduate degree (0.77; 0.68-0.86 for men and 0.77; 0.69-0.86 for women). Parent's gender, cause of death and child's age at the death did not modify the associations. CONCLUSIONS As education impacts population health, support for bereaved school children may be more important than realized.
Collapse
Affiliation(s)
- B L Høeg
- Survivorship Unit, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen, Denmark
| | - C Johansen
- Survivorship Unit, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen, Denmark.,Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - J Christensen
- Statistics, Bioinformatics and Registry Unit, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - K Frederiksen
- Statistics, Bioinformatics and Registry Unit, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - S Oksbjerg Dalton
- Survivorship Unit, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen, Denmark
| | - P Bøge
- Department of Patient Support and Community Activities, Danish Cancer Society, Copenhagen, Denmark
| | - A Dencker
- Department of Patient Support and Community Activities, Danish Cancer Society, Copenhagen, Denmark
| | - A Dyregrov
- Center for Crisis Psychology, Bergen, Norway
| | - P E Bidstrup
- Survivorship Unit, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen, Denmark
| |
Collapse
|
20
|
Soussi BG, Cordtz RL, Kristensen S, Bork CS, Christensen J, Schmidt EB, Prieto-Alhambra D, Dreyer L. OP0068 INCIDENCE AND PREVALENCE OF RHEUMATOID ARTHRITIS IN DENMARK: A NATIONWIDE POPULATION-BASED STUDY INVESTIGATING THE EFFECT OF FOUR DIFFERENT CASE DEFINITIONS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.891] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The incidence rate (IR) and point prevalence (PP) of rheumatoid arthritis (RA) in Denmark is largely unknown. Two challenges in estimating the “true” IR and PP using nationwide registry data are the choice of the RA case definition, and the denominator used, i.e. the exact amount of person years (PY) or census count data.Objectives:To investigate the incidence and prevalence of RA in the adult Danish population using four different case definitions and two different denominator strategies.Methods:Nationwide register-based cohort study. Patients with RA between 1996 and the end of 2016 were identified using the Danish National Patient Registry (DNPR) and information on DMARD prescriptions were obtained through linkage with the Danish National Prescription Registry. Age and sex standardised incidence and prevalence of RA were calculated in different ways: we estimated the IR (denominator = actual recorded number of PY in each year using migration and vital data) and the incidence proportion (IP) (denominator = census count data); and the PP (%) of RA was calculated for years 2000, 2009, 2011 and 2016. The four case definitions were: Model A, a first time RA diagnosis (ICD-10: M05-06) in DNPR and a redeemed prescription of a conventional DMARD in the following year1; Model B, an RA diagnosis recorded twice in DNPR within 90 days with both records originating from a department of rheumatology or general internal medicine2; Model C, any RA diagnosis recorded in DNPR with a DMARD prescription redeemed in the year before or after the diagnosis; Model D, similar to Model A but with the additional requirement that cases had no registered ICD code for inflammatory diseases prior to the RA diagnosis1.Results:The overall IR of RA from 1996 to 2016 based on model A was 35.2 (95%CI 34.8 to 35.6) per 100,000 PY while the IP was 34.7 (95%CI 34.3 to 35.1) per 100,000 individuals. The age standardised IR was higher for women than for men (Figure 1), and this was observed across all age groups. The IR peaked at age 70 to 74 in both men and women. Regardless of which case definition was used, the temporal trend showed a peak in IR in 2010 followed by a plateau (Figure 2). The overall PP estimate for all four models increased from 2000 to 2016, data shown for Model A in Table 1.Table 1.Point prevalence (PP) of rheumatoid arthritis in years 2000, 2009, 2011 and 2016 based on Model A2000N = 590670.3 % women2009N = 1503770.9 % women2011N = 1736371.0 % women2016N = 2299170.3 % womenPP (%) (95% CI)PP (%) (95% CI)PP (%) (95% CI)PP (%) (95% CI)All0.16 (0.15 to 0.16)0.37 (0.36 to 0.37)0.41 (0.41 to 0.42)0.52 (0.51 to 0.52)Women0.21 (0.20 to 0.22)0.50 (0.49 to 0.51)0.57 (0.56 to 0.58)0.71 (0.70 to 0.72)Men0.10 (0.10 to 0.11)0.23 (0.22 to 0.23)0.25 (0.25 to 0.26)0.32 (0.31 to 0.33)Conclusion:A peak in the IR of RA was observed in 2010, regardless of which case definition was used. We believe this was due to introduction of the new EULAR/ACR diagnostic criteria at that time. IP estimates were systematically lower than IRs calculated using exact migration and vital data as denominator. The PP increased over time regardless of which case definition we used. We conclude that the choice of RA case definition had a larger influence than the choice of denominator.References:[1]inauskas A et al. Positive predictive value of first-time rheumatoid arthritis diagnoses and their serological subtypes in the Danish National Patient Registry. Clin Epidemiol. 2018;10:1709-1720.[2]Ibfelt E et al. Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry. Clin Epidemiol. 2017:627-632.Acknowledgments:The study is funded by the Danish Rheumatism Association.Disclosure of Interests:Bolette Gylden Soussi: None declared, René Lindholm Cordtz: None declared, Salome Kristensen: None declared, Christian Sørensen Bork: None declared, Jeppe Christensen: None declared, Erik Berg Schmidt: None declared, Daniel Prieto-Alhambra Grant/research support from: Professor Prieto-Alhambra has received research Grants from AMGEN, UCB Biopharma and Les Laboratoires Servier, Consultant of: DPA’s department has received fees for consultancy services from UCB Biopharma, Speakers bureau: DPA’s department has received fees for speaker and advisory board membership services from Amgen, Lene Dreyer: None declared
Collapse
|
21
|
Gesche J, Christensen J, Hjalgrim H, Rubboli G, Beier CP. Epidemiology and outcome of idiopathic generalized epilepsy in adults. Eur J Neurol 2020; 27:676-684. [DOI: 10.1111/ene.14142] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Accepted: 12/03/2019] [Indexed: 11/28/2022]
Affiliation(s)
- J. Gesche
- Department of Neurology Odense University Hospital Odense Denmark
- Department of Clinical Research University of Southern Denmark Odense Denmark
| | - J. Christensen
- Department of Neurology Aarhus University Hospital Aarhus, Denmark
| | - H. Hjalgrim
- Danish Epilepsy Center Dianalund Denmark
- Amplexa Genetics A/S Odense Denmark
| | - G. Rubboli
- Danish Epilepsy Center Dianalund Denmark
- University of Copenhagen Copenhagen Denmark
| | - C. P. Beier
- Department of Neurology Odense University Hospital Odense Denmark
- Department of Clinical Research University of Southern Denmark Odense Denmark
- OPEN Odense University Hospital Odense Denmark
| |
Collapse
|
22
|
Degett TH, Christensen J, Thomsen LA, Iversen LH, Gögenur I, Dalton SO. Nationwide cohort study of the impact of education, income and social isolation on survival after acute colorectal cancer surgery. BJS Open 2019; 4:133-144. [PMID: 32011820 PMCID: PMC6996631 DOI: 10.1002/bjs5.50218] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 07/16/2019] [Indexed: 12/16/2022] Open
Abstract
Background Acute colorectal cancer surgery has been associated with a high postoperative mortality. The primary aim of this study was to examine the association between socioeconomic position and the likelihood of undergoing acute versus elective colorectal cancer surgery. A secondary aim was to determine 1‐year survival among patients treated with acute surgery. Methods All patients who had undergone a surgical procedure according to the Danish Colorectal Cancer Group (DCCG.dk) database, or who were registered with stent or diverting stoma in the National Patient Register from 2007 to 2015, were reviewed. Socioeconomic position was determined by highest attained educational level, income, urbanicity and cohabitation status, obtained from administrative registries. Co‐variables included age, sex, year of surgery, Charlson Co‐morbidity Index score, smoking status, alcohol consumption, BMI, stage and tumour localization. Logistic regression analysis was performed to determine the likelihood of acute colorectal cancer surgery, and Kaplan–Meier and Cox proportional hazards regression methods were used for analysis of 1‐year overall survival. Results In total, 35 661 patients were included; 5310 (14·9 per cent) had acute surgery. Short and medium education in patients younger than 65 years (odds ratio (OR) 1·58, 95 per cent c.i. 1·32 to 1·91, and OR 1·34, 1·15 to 1·55 respectively), low income (OR 1·12, 1·01 to 1·24) and living alone (OR 1·35, 1·26 to 1·46) were associated with acute surgery. Overall, 40·7 per cent of patients died within 1 year of surgery. Short education (hazard ratio (HR) 1·18, 95 per cent c.i. 1·03 to 1·36), low income (HR 1·16, 1·01 to 1·34) and living alone (HR 1·25, 1·13 to 1·38) were associated with reduced 1‐year survival after acute surgery. Conclusion Low socioeconomic position was associated with an increased likelihood of undergoing acute colorectal cancer surgery, and with reduced 1‐year overall survival after acute surgery.
Collapse
Affiliation(s)
- T H Degett
- Danish Cancer Society Research Center, Copenhagen, Denmark.,Center for Surgical Science, Zealand University Hospital, Køge, Denmark
| | - J Christensen
- Danish Cancer Society Research Center, Copenhagen, Denmark
| | - L A Thomsen
- Danish Cancer Society Research Center, Copenhagen, Denmark
| | - L H Iversen
- Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.,Danish Colorectal Cancer Group, Denmark
| | - I Gögenur
- Center for Surgical Science, Zealand University Hospital, Køge, Denmark.,Danish Colorectal Cancer Group, Denmark
| | - S O Dalton
- Danish Cancer Society Research Center, Copenhagen, Denmark.,Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark
| |
Collapse
|
23
|
Ly CV, Koenig L, Christensen J, Gordon B, Beaumont H, Dahiya S, Chen J, Su Y, Nelson B, Jockel-Balsarotti J, Drain C, Jerome G, Morris JC, Fagan AM, Harms MB, Benzinger TLS, Miller TM, Ances BM. Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. Eur J Neurol 2019; 26:1235-1239. [PMID: 30790403 PMCID: PMC6684398 DOI: 10.1111/ene.13940] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Accepted: 01/21/2019] [Indexed: 01/06/2023]
Abstract
BACKGROUND AND PURPOSE AV-1451 (18 F-AV-1451, flortaucipir) positron emission tomography was performed in C9orf72 expansion carriers to assess tau accumulation and disease manifestation. METHODS Nine clinically characterized C9orf72 expansion carriers and 18 age- and gender- matched cognitively normal individuals were psychometrically evaluated and underwent tau positron emission tomography imaging. The regional AV-1451 standard uptake value ratios from multiple brain regions were analyzed. Spearman correlation was performed to relate the AV-1451 standard uptake value ratio to clinical, psychometric and cerebrospinal fluid measures. RESULTS C9orf72 expansion carriers had increased AV-1451 binding in the entorhinal cortex compared to controls. Primary age-related tauopathy was observed postmortem in one patient. AV-1451 uptake did not correlate with clinical severity, disease duration, psychometric performance or cerebrospinal fluid markers. CONCLUSION C9orf72 expansion carriers exhibited increased AV-1451 uptake in entorhinal cortex compared to cognitively normal controls, suggesting a propensity for primary age-related tauopathy. However, AV-1451 accumulation was not associated with psychometric performance in our cohort.
Collapse
Affiliation(s)
- C V Ly
- Department of Neurology, Washington University, Saint Louis, MO, USA
| | - L Koenig
- Department of Radiology, Washington University, Saint Louis, MO, USA
| | - J Christensen
- Department of Radiology, Washington University, Saint Louis, MO, USA
| | - B Gordon
- Department of Radiology, Washington University, Saint Louis, MO, USA
- Knight Alzheimer's Disease Research Center, Washington University, Saint Louis, MO, USA
| | - H Beaumont
- Department of Neurology, Washington University, Saint Louis, MO, USA
| | - S Dahiya
- Department of Pathology and Immunology, Washington University, Saint Louis, MO, USA
| | - J Chen
- Department of Pathology and Immunology, Washington University, Saint Louis, MO, USA
| | - Y Su
- Banner Alzheimer's Institute, Phoenix, AZ, USA
| | - B Nelson
- Department of Neurology, Washington University, Saint Louis, MO, USA
| | | | - C Drain
- Department of Neurology, Washington University, Saint Louis, MO, USA
| | - G Jerome
- Department of Neurology, Washington University, Saint Louis, MO, USA
| | - J C Morris
- Department of Neurology, Washington University, Saint Louis, MO, USA
- Knight Alzheimer's Disease Research Center, Washington University, Saint Louis, MO, USA
| | - A M Fagan
- Department of Neurology, Washington University, Saint Louis, MO, USA
- Knight Alzheimer's Disease Research Center, Washington University, Saint Louis, MO, USA
- Hope Center for Neurological Disorders, Washington University, Saint Louis, MO, USA
| | - M B Harms
- Department of Neurology, Columbia University, New York, NY, USA
| | - T L S Benzinger
- Department of Radiology, Washington University, Saint Louis, MO, USA
- Knight Alzheimer's Disease Research Center, Washington University, Saint Louis, MO, USA
- Department of Neurosurgery, Washington University, Saint Louis, MO, USA
| | - T M Miller
- Department of Neurology, Washington University, Saint Louis, MO, USA
- Hope Center for Neurological Disorders, Washington University, Saint Louis, MO, USA
| | - B M Ances
- Department of Neurology, Washington University, Saint Louis, MO, USA
- Department of Radiology, Washington University, Saint Louis, MO, USA
- Knight Alzheimer's Disease Research Center, Washington University, Saint Louis, MO, USA
- Hope Center for Neurological Disorders, Washington University, Saint Louis, MO, USA
| |
Collapse
|
24
|
Papadopoulos KP, Ou SHI, Johnson ML, Christensen J, Velastegui K, Potvin D, Faltaos D, Chao RC. A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.tps3161] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS3161 Background: RAS proteins are part of the family of small GTPases which regulate intracellular signaling pathways responsible for cell growth, migration, survival and differentiation. Oncogenic point mutations in RAS in codons 12, 13, and 61 occur in up to one-third of all human cancers and result in constitutive activation of RAS signaling, playing a key role in uncontrolled cellular growth and malignant transformation. Mutant KRASG12C in particular comprises approximately 14% of lung adenocarcinoma and 4% of colon adenocarcinoma, and less commonly in certain other types of cancer. For decades, KRAS was considered undruggable due to its high affinity for GTP/GDP and the lack of a clear binding pocket. Recent discoveries have enabled the development of compounds, including MRTX849, that covalently bind to KRASG12C at the cysteine at residue 12, lock the protein in its inactive GDP-bound conformation, and inhibit KRAS-dependent signal transduction. MRTX849 is a potent, orally-available, mutation-selective small molecule covalent inhibitor of KRASG12C. MRTX849 inhibits KRASG12C signaling in cell lines harboring this mutation, and results in tumor regression in a broad spectrum of KRASG12C animal models. Methods: This multi-center, Phase 1/2, multiple expansion cohort trial evaluates the safety, pharmacokinetics (PK), metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumor malignancies with a KRAS (p.G12C) mutation. The study starts with an evaluation of dose and regimen of MRTX849 using a combination of the accelerated titration and modified toxicity probability interval designs, with MRTX849 initially administered once daily in a continuous regimen expressed in 3-week cycles. As potentially viable regimens are identified, Phase 1b expansion cohorts will be opened to provide greater safety and PK data for determination of the recommended Phase 2 dose (RP2D) and regimen. In Phase 2, separate cohorts of patients by histological diagnosis, including non-small cell lung cancer, colorectal, and other solid tumors, will be enrolled and evaluated for clinical activity using a predictive probability design. The study is open for enrollment, and recruitment is ongoing. Clinical trial information: NCT03785249.
Collapse
|
25
|
Doshi GK, Vogelzang NJ, Richards DA, Chong D, Shaffer DR, Nordquist LT, Picus J, Alvarez D, Der-Torossian H, Christensen J, Yorio JT. Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.7_suppl.tps498] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS498 Background: Combination therapy with agents targeting molecular and cellular mechanisms of CIT resistance is a rational approach to restoring CIT efficacy in patients (pts) with immunotherapy-resistant UC. Sitravatinib is a tyrosine kinase inhibitor (TKI) that targets multiple closely-related receptor tyrosine kinase (RTK) pathways, including the split RTKs VEGFR-2 and KIT, as well as the TAM (TYRO3, AXL, and MER) RTKs. Inhibition of the split RTKs enhances antitumor activity by reduction of immunosuppressive regulatory T cells and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME). Inhibition of TAM RTKs further restores a more immune-supportive TME by depletion of MDSCs and repolarization of tumor-associated macrophages to the M1 phenotype associated with secretion of pro-inflammatory cytokines. Given these pleiotropic immune-activating effects, the combination of sitravatinib with nivolumab is a rational approach to restoring or enhancing CIT clinical activity in pts with immunotherapy-resistant UC. This combination has been shown to be safe and tolerable in an ongoing Phase 2 study in pts with metastatic non-small cell lung cancer. Methods: This open-label Phase 2 study evaluates tolerability and clinical activity of sitravatinib in combination with nivolumab in pts with advanced or metastatic UC who experienced disease progression on or after CIT as the most recent systemic therapy. Enrollment is stratified by prior receipt of platinum-based chemotherapy. If the initial 2 cohorts are of high interest for efficacy, the protocol allows for addition of new cohorts to include pts previously treated with selected immunotherapies (anti-CTLA-4, anti-OX40 or anti–CD137 therapy) or who are CIT-naïve. The primary objective is Objective Response Rate. A Predictive Probability Design will be applied allowing for expansion to 40 pts per cohort. Sitravatinib is administered orally daily in continuous 28-day cycles at 120 mg; nivolumab intravenously at 240 mg every 2 weeks or 480 mg every 4 weeks. Status: The study is open for enrollment and recruitment is ongoing. Clinical trial information: NCT03606174.
Collapse
Affiliation(s)
| | | | | | - Daniel Chong
- Virginia Cancer Specialists, US Oncology Research, Fairfax, VA
| | | | | | - Joel Picus
- Washington University in St. Louis School of Medicine, St. Louis, MO
| | | | | | | | | |
Collapse
|
26
|
Meert K, Slomine BS, Silverstein FS, Christensen J, Ichord R, Telford R, Holubkov R, Dean JM, Moler FW. One-year cognitive and neurologic outcomes in survivors of paediatric extracorporeal cardiopulmonary resuscitation. Resuscitation 2019; 139:299-307. [PMID: 30818016 DOI: 10.1016/j.resuscitation.2019.02.023] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 01/31/2019] [Accepted: 02/18/2019] [Indexed: 12/19/2022]
Abstract
OBJECTIVE To describe one-year cognitive and neurologic outcomes among extracorporeal cardiopulmonary resuscitation (ECPR) survivors enrolled in the Therapeutic Hypothermia after Paediatric Cardiac Arrest In-Hospital (THAPCA-IH) trial; and compare outcomes between survivors who received ECPR, later extracorporeal membrane oxygenation (ECMO), or no ECMO. METHODS All children recruited to THAPCA-IH were comatose post-arrest. Neurobehavioral function was assessed by caregivers using the Vineland Adaptive Behaviour Scales, 2nd edition (VABS-II) at pre-arrest baseline and 12 months post-arrest. Age-appropriate cognitive performance measures (Mullen Scales of Early Learning or Wechsler Abbreviated Scale of Intelligence) and neurologic examinations were obtained 12 months post-arrest. VABS-II and cognitive performance measures were transformed to standard scores (mean = 100, SD = 15) with higher scores representing better performance. Only children with broadly normal pre-arrest function (VABS-II ≥70) were included in this analysis. RESULTS One-year follow-up was attained for 127 survivors with pre-arrest VABS-II ≥70. Of these, 57 received ECPR, 14 received ECMO later in their course, and 56 did not receive ECMO. VABS-II assessments were completed at 12 months for 55 (96.5%) ECPR survivors, cognitive testing for 44 (77.2%) and neurologic examination for 47 (82.5%). At 12 months, 39 (70.9%) ECPR survivors had VABS-II scores ≥70. On cognitive testing, 24 (54.6%) had scores ≥70, and on neurologic examination, 28 (59.5%) had no/minimal to mild impairment. Cognitive and neurologic score distributions were similar between ECPR, later ECMO and no ECMO groups. CONCLUSIONS Many ECPR survivors had favourable outcomes although impairments were common. ECPR survivors had similar outcomes to other survivors who were initially comatose post-arrest.
Collapse
Affiliation(s)
- Kathleen Meert
- Children's Hospital of Michigan, Wayne State University, 3901 Beaubien Boulevard, Detroit, MI, 48201, USA.
| | - Beth S Slomine
- Kennedy Krieger Institute, Johns Hopkins University, 707 North Broadway, Baltimore, MD, 21205, USA
| | | | - James Christensen
- Kennedy Krieger Institute, Johns Hopkins University, 707 North Broadway, Baltimore, MD, 21205, USA
| | - Rebecca Ichord
- Children's Hospital of Philadelphia, University of Pennsylvania, 3410 Civic Center Boulevard, Philadelphia, PA, 19104, USA
| | - Russell Telford
- University of Utah, 295 Chipeta Way, P.O. Box 581289, Salt Lake City, UT, 84158, USA
| | - Richard Holubkov
- University of Utah, 295 Chipeta Way, P.O. Box 581289, Salt Lake City, UT, 84158, USA
| | - J Michael Dean
- University of Utah, 295 Chipeta Way, P.O. Box 581289, Salt Lake City, UT, 84158, USA
| | - Frank W Moler
- CS Mott Children's Hospital, University of Michigan, 1500 East Hospital Drive, Ann Arbor, MI, 48109-5636, USA
| | | |
Collapse
|
27
|
Moler FW, Silverstein FS, Nadkarni VM, Meert KL, Shah SH, Slomine B, Christensen J, Holubkov R, Page K, Dean JM. Pediatric out-of-hospital cardiac arrest: Time to goal target temperature and outcomes. Resuscitation 2018; 135:88-97. [PMID: 30572071 DOI: 10.1016/j.resuscitation.2018.12.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 11/26/2018] [Accepted: 12/10/2018] [Indexed: 01/11/2023]
Abstract
AIM Although recent out-of-hospital cardiac arrest (CA) trials found no benefits of hypothermia versus normothermia targeted temperature management, preclinical models suggest earlier timing of hypothermia improves neuroprotective efficacy. This study investigated whether shorter time to goal temperature was associated with better one-year outcomes in the Therapeutic Hypothermia After Pediatric Cardiac Arrest Out-of-Hospital Trial. METHODS Patients were classified by tertiles of time to attain assigned goal temperature range (32-34°C or 36-37.5°C) following ROSC. Outcomes in the first tertile ("earlier") Group 1 were compared with second and third tertiles ("later") Group 2. Separate analyses were, additionally, completed for hypothermia and normothermia intervention groups. Three one-year outcomes were examined: survival; Vineland Adaptive Behavior Scale (VABS-II) score≥70; and decrease in VABS-II≤15 points from baseline. RESULTS In the entire cohort (n=281), median time from ROSC to goal temperature was 7.4 [IQR 6.2-9.7] hours: Group 1, 5.8 [IQR 5.2, 6.2] and Group 2, 8.8 [IQR 7.4, 10.4] h. Outcomes did not differ between these groups. For hypothermia subgroup, survival was lower in Group 1 than 2, [10/49(20%) versus 47/99(47%), p<0.002], with a trend toward fewer with VABS-II scores≥70 and change in VABS-II≤15 points (p=0.07-0.08). For normothermia subgroup, there was a trend toward higher survival in Group 1 than 2 [18/42(43%) versus 21/83(25%), p=0.065], but no differences in VABS-II-related measures. In multivariable logistic regression models, no difference in earlier and later groups or temperature intervention was observed. CONCLUSION We found no evidence that earlier time to goal temperature was associated with better outcomes.
Collapse
Affiliation(s)
- Frank W Moler
- University of Michigan Medical School, Ann Arbor, MI, United States.
| | | | - Vinay M Nadkarni
- Children's Hospital of Philadelphia, Philadelphia, PA, United States
| | - Kathleen L Meert
- Children's Hospital of Michigan, Wayne State University, Detroit, MI, United States
| | - Samir H Shah
- University of Tennessee Health Sciences Center, United States
| | - Beth Slomine
- Kennedy Krieger Institute and Johns Hopkins University, Baltimore, MD, United States
| | - James Christensen
- Kennedy Krieger Institute and Johns Hopkins University, Baltimore, MD, United States
| | | | - Kent Page
- University of Utah, Salt Lake City, UT, United States
| | | | | |
Collapse
|
28
|
Jacobs MT, Mohindra NA, Shantzer L, Chen IL, Phull H, Mitchell W, Raymond VM, Banks KC, Nagy RJ, Lanman RB, Christensen J, Patel JD, Clarke J, Patel SP. Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non–Small-Cell Lung Cancer: A Multicenter Case Series. JCO Precis Oncol 2018; 2:1-10. [DOI: 10.1200/po.17.00318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To evaluate the clinical outcome of patients with non–small-cell lung cancer treated by targeting low variant allelic frequency (VAF) driver mutations identified through cell-free DNA (cfDNA) next-generation sequencing (NGS). Detection of driver mutations in cancer is critically important in the age of targeted therapy, where both tumor-based as well as cfDNA sequencing methods have been used for therapeutic decision making. We hypothesized that VAF should not be predictive of response and that low VAF alterations detected by cfDNA NGS can respond to targeted therapy. Patients and Methods A multicenter retrospective case review was performed to identify patients with non–small-cell lung cancer who received targeted molecular therapy on the basis of findings of low VAF alterations in cfDNA NGS. Mutations at low VAF were defined as < 0.2% mutated cfDNA molecules in a background of wild-type cfDNA. Results One hundred seventy-two patients underwent cfDNA NGS testing. Of the 172 patients, 12 were identified as having low VAF driver alterations and were considered for targeted therapy. The median progression-free survival (PFS) for all patients was 52 weeks (range, 17 to 88 weeks). For patients with EGFR exon 19 deletion (n = 7), the median PFS was 52 weeks (range, 17 to 60.5 weeks). For patients with EML4-ALK fusions (n = 3), the median PFS was 60 weeks (range, 18 to 88 weeks). The median overall survival for all patients after diagnosis was 57.6 weeks. Conclusion Targeted treatment response for driver mutations detected by cfDNA may be independent of VAF, even in relation to other higher VAF aberrations in plasma, and directly dependent on the underlying disease biology and ability to treat the patient with appropriate targeted therapy.
Collapse
Affiliation(s)
- Miriam T. Jacobs
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Nisha A. Mohindra
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Lindsey Shantzer
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Ingrid L. Chen
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Hardeep Phull
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - William Mitchell
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Victoria M. Raymond
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Kimberly C. Banks
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Rebecca J. Nagy
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Richard B. Lanman
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - James Christensen
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Jyoti D. Patel
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Jeffrey Clarke
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| | - Sandip P. Patel
- Miriam T. Jacobs, Washington University School of Medicine in St Louis, St Louis, MO; Nisha A. Mohindra, Northwestern University; Jyoti D. Patel, University of Chicago School of Medicine, Chicago, IL; Lindsey Shantzer and Jeffrey Clarke, Duke University Medical Center, Durham, NC; Ingrid L. Chen, Stony Brook University School of Medicine, Stony Brook, NY; Hardeep Phull, William Mitchell, and Sandip P. Patel, University of California, San Diego, La Jolla; Victoria M. Raymond, Kimberly C. Banks, Rebecca J
| |
Collapse
|
29
|
Majano SB, Di Girolamo C, Maringe C, Walters S, Morris M, Guren M, Glimelius B, Iversen L, Schnell E, Lundqvist K, Christensen J, Coleman M, Rachet B. Treatment and Survival From Colorectal Cancer in Denmark, England, Norway, and Sweden: A Population-Based Study. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.52300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: Colorectal cancer (CRC) patients in Denmark and England have historically had worse outcomes than patients diagnosed in other high-income countries with similar healthcare coverage. This survival deficit may be partly explained by differences in stage distribution due to delays in cancer diagnosis, however, differences in stage-specific survival suggest that differences in treatment also explain the survival gap. Aim: We aim to provide a comparison of stage-specific survival of CRC patients diagnosed in Denmark, England, Norway and Sweden, and compare the probability of receiving potentially curative surgery (PCS) by patient and tumor characteristics to understand whether differences in stage and treatment help explain the international differences in survival. Methods: Population-based information on patients aged 18-99 years diagnosed with primary malignant colon or rectal cancer in Denmark, England, Norway, and Sweden during 2010-2012 was extracted from national CRC registries. We compared the prevalence of PCS by stage and age category, and estimated the probability of receiving it using multivariate logistic regression. Age-standardized net survival was estimated using a multivariable modeling approach. Results: There were 13,230 patients diagnosed with CRC in Denmark, 99,869 in England, 11,754 in Norway, and 17,584 in Sweden between 2010 and 2012. The proportion of patients with missing stage information was higher in England than in the other countries. Stage distribution was otherwise similar. Survival of patients with stage I-II tumors was generally comparable between the countries, but lower in England and - to a lesser degree - in Denmark for stage III-IV disease. Patients with unknown stage had lower survival than staged patients in all countries. We found marked disadvantages in the probability of receiving PCS in older patients with stage II-IV disease in England, and stage IV colon cancer patients in Denmark. The proportion of surgically-treated rectal cancer patients (and their survival) was comparable between Denmark, Norway and Sweden for each combination of age group and stage, except for patients diagnosed with stage I disease. The proportion of patients receiving surgery and survival from rectal cancer was generally lower in England. Conclusion: Denmark seems to be catching up with Norway and Sweden, especially in rectal cancer survival. Despite recent improvements, CRC survival in England remains lower than in Sweden and Norway. Survival generally paralleled countries' relative performance in the provision of potentially curative surgery. Differences in patient selection for surgery, especially in older patients and/or with advanced disease, may partly explain the survival deficit. Increases in the proportion treated, in combination with efforts in postoperative care and with other treatment modalities, may translate into better longer-term outcomes, especially for frail patients.
Collapse
Affiliation(s)
- S. Benitez Majano
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - C. Di Girolamo
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - C. Maringe
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - S. Walters
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - M. Morris
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - M.G. Guren
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - B. Glimelius
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - L. Iversen
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - E. Schnell
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - K. Lundqvist
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - J. Christensen
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - M.P. Coleman
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - B. Rachet
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| |
Collapse
|
30
|
Leal T, Spira A, Blakely C, He K, Berz D, Richards D, Uyeki J, Savage A, Roque T, Massarelli E, Jotte R, Chen I, Christensen J, Olson P, Tassell V, Horn L. Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Bazhenova L, Carvajal R, Cho B, Eaton K, Goel S, Heist R, Ingham M, Wang D, Werner T, Neuteboom S, Potvin D, Chen I, Christensen J, Chao R, Alva A. Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Tovar E, Essenburg C, Peck A, Turner L, Madaj Z, Smith M, Christensen J, Melnik M, Haura E, Steensma M, Graveel C. Abstract A48: MET and EGFR interaction promotes acquired resistance to kinase inhibition in TNBC. Mol Cancer Res 2018. [DOI: 10.1158/1557-3125.advbc17-a48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancers, and the molecular heterogeneity within TNBC heightens the challenge of developing effective targeted therapies. Receptor tyrosine kinases (RTKs), in particular MET and EGFR, are promising therapeutic targets for TNBC due to their high expression in multiple molecular TNBC subtypes and the tendency for cancers to become “kinase addicted.” We and others have demonstrated that MET is highly expressed in TNBC and its expression correlates with poor prognosis. EGFR expression is also elevated in up to 72% of TNBCs and correlates with poor prognosis in TNBC patients. Recently, we demonstrated that MET and EGFR are coordinately and highly expressed across all TNBC subtypes and the efficacy of combined MET and EGFR inhibition in TNBC patient-derived xenograft (PDX) models. Even though MET and EGFR receptors are actionable targets due to their high activity in TNBC, crosstalk between MET and EGFR has been implicated in therapeutic resistance to kinase inhibitors in several cancer types and needs to be evaluated in TNBC.
There is strong evidence demonstrating the critical role of redundant RTK signaling networks in resistance to tyrosine kinase inhibitors (TKIs). Specifically, crosstalk between MET and EGFR has been implicated in therapeutic resistance to EGFR or MET inhibitors in colon, gastric, and lung cancers. Since MET and EGFR are highly expressed in a substantial proportion of TNBCs, we used TNBC PDX models and TNBC cell lines to interrogate mechanisms of resistance to MET and EGFR kinase inhibition. We hypothesized that coexpression, interaction, and activation of MET and EGFR promote acquired TKI resistance and an adaptive kinome response in TNBC. Using TNBC PDX models that highly express both MET and EGFR, we evaluated MET and EGFR activity, localization, and interaction after 3 days or 3 weeks of treatment with MET (glesatinib, crizotinib) and/or EGFR inhibitors (erlotinib). After 3 weeks of dual MET and EGFR inhibition in TNBC PDXs, only a small population of “resistant” cells remained. In these resistant populations, we observed increased MET and EGFR colocalization and increased MET and EGFR activation. To understand how colocalization of MET and EGFR promotes signaling redundancy and crosstalk, we asked whether MET and EGFR directly interact in TNBC PDX using a proximity ligation assay (PLA). PLA uses antibody specificity to detect direct protein-protein interactions at physiologic levels in vitro and in vivo. We observed a significant increase in MET EGFR interactions only in resistant cell populations that had been treated with both MET and EGFR inhibitors. AKT and ERK signaling were also increased in TKI-resistant cells, indicating that these are key survival pathways in resistance. Interestingly, we did not observe an increase in MET-EGFR activity or interaction in PDX tumors treated for only 3 days. Even though TNBC cells (HCC70) showed increased colocalization of MET and EGFR with combined glesatinib and erlotinib treatment, there was not a significant increase in MET-EGFR interactions. Evaluation of MET-EGFR interaction in primary TNBC patient samples revealed significant MET-EGFR interactions in a MET-amplified tumor and lymph node metastases. To our knowledge, this is the first time MET-EGFR interactions have been observed in TNBC in vivo and in human patients. Moreover, MET-EGFR interactions are able to maintain MET, EGFR, ERK, and AKT activity through a yet-unknown mechanism. These results imply that MET EGFR interaction may be a unique mechanism of resistance to kinase inhibition that may be inherent in human TNBCs with genomic amplification of MET or EGFR.
Citation Format: Elizabeth Tovar, Curt Essenburg, Anderson Peck, Lisa Turner, Zachary Madaj, Matthew Smith, James Christensen, Marianne Melnik, Eric Haura, Matthew Steensma, Carrie Graveel. MET and EGFR interaction promotes acquired resistance to kinase inhibition in TNBC [abstract]. In: Proceedings of the AACR Special Conference: Advances in Breast Cancer Research; 2017 Oct 7-10; Hollywood, CA. Philadelphia (PA): AACR; Mol Cancer Res 2018;16(8_Suppl):Abstract nr A48.
Collapse
Affiliation(s)
| | | | | | - Lisa Turner
- 1Van Andel Research Institute, Grand Rapids, MI,
| | | | - Matthew Smith
- 2Moffit Cancer Center and Research Institute, Tampa, FL,
| | | | | | - Eric Haura
- 2Moffit Cancer Center and Research Institute, Tampa, FL,
| | | | | |
Collapse
|
33
|
Abstract
The valley can serve as a new degree of freedom in the manipulation of particles or waves in condensed matter physics, whereas systems containing combinations of gain and loss elements constitute rich building units that can mimic non-Hermitian properties. By introducing gain and loss in artificial acoustic boron nitride, we show that the acoustic valley states and the valley-projected edge states display exotic behaviors in that they sustain either attenuated or amplified wave propagation. Our findings show how non-Hermiticity introduces a mechanism in tuning topological protected valley transports, which may have significance in advanced wave control for sensing and communication applications.
Collapse
Affiliation(s)
- Mudi Wang
- Key Laboratory of Artificial Micro- and Nano-structures of Ministry of Education and School of Physics and Technology, Wuhan University, Wuhan 430072, China
| | - Liping Ye
- Key Laboratory of Artificial Micro- and Nano-structures of Ministry of Education and School of Physics and Technology, Wuhan University, Wuhan 430072, China
| | - J Christensen
- Department of Physics, Universidad Carlos III de Madrid, Avenida de la Universidad 30, 28916 Leganes (Madrid), Spain
| | - Zhengyou Liu
- Key Laboratory of Artificial Micro- and Nano-structures of Ministry of Education and School of Physics and Technology, Wuhan University, Wuhan 430072, China
- Institute for Advanced Studies, Wuhan University, Wuhan 430072, China
| |
Collapse
|
34
|
Ichord R, Silverstein FS, Slomine BS, Telford R, Christensen J, Holubkov R, Dean JM, Moler FW. Neurologic outcomes in pediatric cardiac arrest survivors enrolled in the THAPCA trials. Neurology 2018; 91:e123-e131. [PMID: 29884735 DOI: 10.1212/wnl.0000000000005773] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2017] [Accepted: 04/09/2018] [Indexed: 01/04/2023] Open
Abstract
OBJECTIVE To implement a standardized approach to characterize neurologic outcomes among 12-month survivors in the Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA) trials. METHODS Two multicenter trials enrolled children age 48 hours to 18 years who remained comatose after cardiac arrest (CA) occurring out-of-hospital (THAPCA-OH, NCT00878644) or in-hospital (THAPCA-IH, NCT00880087); patients were randomized to therapeutic hypothermia or therapeutic normothermia. The primary outcome, survival with favorable 12-month neurobehavioral outcome (Vineland Adaptive Behavior Scales [VABS-II]), did not differ between treatment groups in either trial. Neurologists examined 181 12-month survivors, described findings using the novel semi-quantitative Pediatric Resuscitation after Cardiac Arrest (PRCA) form, and rated findings in 6 domains; scores ranged from 0 (no deficits) to 21 (maximal deficits). PRCA scores were compared with 12-month VABS-II scores and cognitive scores. RESULTS Neurologic outcome PRCA scores were classified as no/minimal impairment, PRCA 0-3, 81/179 (45%); mild impairment, PRCA 4-7, 24/179 (13%); moderate impairment, PRCA 8-11, 15/179 (8%); severe impairment, PRCA 12-16, 20/179 (11%); profound impairment, PRCA 17-21, 39/179 (21%) (2/181 incomplete). VABS-II scores correlated strongly with PRCA category (r = -0.88, p < 0.0001, Pearson correlation coefficient) and cognitive scores (r = -0.72, p < 0.0001). Factors associated with poor outcomes included out-of-hospital CA, seizure recognition in the early postarrest period, and poor neurologic status at hospital discharge. CONCLUSION The PRCA provides a robust method for depicting neurologic outcomes after acute encephalopathy caused by CA in children. It provides a global semiquantitative rating of neurologic impairment and domain-specific impairment. The strong correlation with well-established neurobehavioral outcome measures supports its validity over a broad age range and wide spectrum of outcomes.
Collapse
Affiliation(s)
- Rebecca Ichord
- From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City.
| | - Faye S Silverstein
- From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City
| | - Beth S Slomine
- From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City
| | - Russell Telford
- From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City
| | - James Christensen
- From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City
| | - Richard Holubkov
- From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City
| | - J Michael Dean
- From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City
| | - Frank W Moler
- From the Department of Neurology & Pediatrics (R.I.), Children's Hospital of Philadelphia, Perelman School of Medicine of the University of Pennsylvania; University of Michigan (F.S.S., F.W.M.), Ann Arbor; Kennedy Krieger Institute and Johns Hopkins University (B.S.S., J.C.), Baltimore, MD; and University of Utah (R.T., R.H., J.M.D.), Salt Lake City
| | | |
Collapse
|
35
|
Pant S, Spira AI, Cho BC, Goel S, Hoimes CJ, Alva AS, Balaraman R, Bauer TM, Lowry PA, Ramaekers RC, Siegel RD, Werner TL, Tannir NM, Faltaos D, Potvin D, Neuteboom ST, Christensen J, Chao RC, Kyriakopoulos C. Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.4568] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Shubham Pant
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Sanjay Goel
- Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
| | - Christopher J. Hoimes
- University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH
| | | | | | | | | | | | | | | | - Nizar M. Tannir
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | | | | |
Collapse
|
36
|
Olsen R, Kudirkiene E, Thøfner I, Pors S, Karlskov-Mortensen P, Li L, Papasolomontos S, Angastiniotou C, Christensen J. Impact of egg disinfection of hatching eggs on the eggshell microbiome and bacterial load. Poult Sci 2018; 96:3901-3911. [PMID: 29050418 DOI: 10.3382/ps/pex182] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Accepted: 06/13/2017] [Indexed: 11/20/2022] Open
Abstract
Disinfection of hatching eggs is essential to ensure high quality production of broilers. Different protocols are followed in different hatcheries; however, only limited scientific evidence on how the disinfection procedures impact the microbiome is available. The aim of the present study was to characterize the microbiome and aerobic bacterial load of hatching eggs before disinfection and during the subsequent disinfection steps. The study included a group of visibly clean and a group of visibly dirty eggs. For dirty eggs, an initial wash in chlorine was performed, hereafter all eggs were submitted to two times fumigation and finally spray disinfection. The eggshell microbiome was characterized by sequencing of the total amount of 16S rRNA extracted from each sample, consisting of shell surface swabs of five eggs from the same group. In addition, the number of colony forming units (cfu) under aerobic conditions was established for each disinfection step. The disinfection procedure reduced the bacterial load from more than 104 cfu (initially visibly clean eggs) and 105 cfu (initially visibly dirty eggs) to less than 10 cfu per sample after disinfection for both groups of eggs. The microbiome of both initially visibly clean and initially visibly dirty eggs had the highest abundances of the phyla Firmicutes, Proteobacteria and Bacteroidetes. Within the phyla Firmicutes the relative abundances of Clostridiales decreased while Lactobacillus increased from before to after final disinfection. In conclusion, the investigated disinfection procedure is effective in reducing the bacterial load, and by adding a chlorine wash for initially visibly dirty eggs, the microbiome of initially visibly clean and initially visibly dirty eggs had a highly similar microflora after the final disinfection step.
Collapse
Affiliation(s)
- R Olsen
- Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | - E Kudirkiene
- Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | - I Thøfner
- Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | - S Pors
- Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | - P Karlskov-Mortensen
- Department of Veterinary Clinical and Animal Science, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | - L Li
- College of Light Industry and Food Sciences, South China University of Technology, China
| | | | | | - J Christensen
- Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| |
Collapse
|
37
|
Hefron R, Borghetti B, Schubert Kabban C, Christensen J, Estepp J. Cross-Participant EEG-Based Assessment of Cognitive Workload Using Multi-Path Convolutional Recurrent Neural Networks. Sensors (Basel) 2018; 18:E1339. [PMID: 29701668 PMCID: PMC5982227 DOI: 10.3390/s18051339] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 04/18/2018] [Accepted: 04/19/2018] [Indexed: 11/22/2022]
Abstract
Applying deep learning methods to electroencephalograph (EEG) data for cognitive state assessment has yielded improvements over previous modeling methods. However, research focused on cross-participant cognitive workload modeling using these techniques is underrepresented. We study the problem of cross-participant state estimation in a non-stimulus-locked task environment, where a trained model is used to make workload estimates on a new participant who is not represented in the training set. Using experimental data from the Multi-Attribute Task Battery (MATB) environment, a variety of deep neural network models are evaluated in the trade-space of computational efficiency, model accuracy, variance and temporal specificity yielding three important contributions: (1) The performance of ensembles of individually-trained models is statistically indistinguishable from group-trained methods at most sequence lengths. These ensembles can be trained for a fraction of the computational cost compared to group-trained methods and enable simpler model updates. (2) While increasing temporal sequence length improves mean accuracy, it is not sufficient to overcome distributional dissimilarities between individuals’ EEG data, as it results in statistically significant increases in cross-participant variance. (3) Compared to all other networks evaluated, a novel convolutional-recurrent model using multi-path subnetworks and bi-directional, residual recurrent layers resulted in statistically significant increases in predictive accuracy and decreases in cross-participant variance.
Collapse
Affiliation(s)
- Ryan Hefron
- Department of Electrical & Computer Engineering, Air Force Institute of Technology, WPAFB, Dayton, OH 45433, USA.
| | - Brett Borghetti
- Department of Electrical & Computer Engineering, Air Force Institute of Technology, WPAFB, Dayton, OH 45433, USA.
| | - Christine Schubert Kabban
- Department of Mathematics & Statistics, Air Force Institute of Technology, WPAFB, Dayton, OH 45433, USA.
| | | | - Justin Estepp
- Air Force Research Laboratory, WPAFB, Dayton, OH 45433, USA.
| |
Collapse
|
38
|
Mirzapoiazova T, Tan C, Wang J, Mambetsariev I, Mambetsariev B, Kulkarni P, Pozhitkov A, Wang Y, Christensen J, Engstrom L, Salgia R. Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Non‐small Cell Lung Cancer and Malignant Mesothelioma. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.835.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Tamara Mirzapoiazova
- Department of Medical Oncology & Therapeutics ResearchCity of Hope National Medical CenterMonroviaCA
| | - Carol Tan
- Department of Medicine, Section of Hematology/ OncologyThe University of ChicagoChicagoIL
| | - Jiale Wang
- Department of Medical Oncology & Therapeutics ResearchCity of Hope National Medical CenterMonroviaCA
| | - Isa Mambetsariev
- Department of Medical Oncology & Therapeutics ResearchCity of Hope National Medical CenterMonroviaCA
| | - Bolot Mambetsariev
- Department of Medical Oncology & Therapeutics ResearchCity of Hope National Medical CenterMonroviaCA
| | - Prakash Kulkarni
- Department of Medical Oncology & Therapeutics ResearchCity of Hope National Medical CenterMonroviaCA
| | - Alex Pozhitkov
- Division of Research InformaticsCity of Hope National Medical CenterIrwindaleCA
| | - Yingyu Wang
- Division of Research InformaticsCity of Hope National Medical CenterIrwindaleCA
| | | | - Lars Engstrom
- Mirati Therapeutics Inc., Mirati Therapeutics Inc.San DiegoCA
| | - Ravi Salgia
- Department of Medical Oncology & Therapeutics ResearchCity of Hope National Medical CenterDuarteCA
| |
Collapse
|
39
|
Kyrø C, Kristensen M, Jakobsen MU, Halkjær J, Landberg R, Bueno-de-Mesquita HA, Christensen J, Romieu I, Tjønneland A, Olsen A. Dietary intake of whole grains and plasma alkylresorcinol concentrations in relation to changes in anthropometry: the Danish diet, cancer and health cohort study. Eur J Clin Nutr 2017; 71:944-952. [PMID: 28176776 DOI: 10.1038/ejcn.2016.233] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 09/29/2016] [Accepted: 10/19/2016] [Indexed: 02/05/2023]
Abstract
BACKGROUND/OBJECTIVES Whole grain intake has been associated with a small but significant lower body weight gain in observational studies, but there is limited knowledge about the associations with specific whole grain types. The objective was to investigate the association between whole grains, different sources of whole grains and biomarkers of whole grain intake (alkylresorcinols) in relation to subsequent changes in waist circumference (WC) and body weight. SUBJECTS/METHODS Cohort study of 57 053 participants with baseline information on whole grain intake from questionnaires (FFQ) and biomarkers of whole grain rye and wheat intake, plasma alkylresorcinols, for a subset. WC and body weight were measured at baseline and again at follow-up. The associations were estimated using multiple linear regression analyses and logistic regression. RESULTS For women, overall whole grain intake was not related to changes in WC or body weight. For men, total whole grain intake was associated with gains in WC (ΔWC per 25 g increment: 0.44 cm, 95% CI: 0.34 cm; 0.54 cm) and body weight (Δweight per 25 g increment: 150 g, 95% CI: 78 g; 222 g), but the results changed to null or changed direction when adjusting for baseline anthropometry. For the different sources of whole grains, rye (women) and crispbread was significantly associated with gains in WC and body weight. Plasma alkylresorcinol concentration was associated with reduced WC, but not body weight, for women (ΔWC per 50 nmol/l increment: -0.69 cm, 95% CI:-1.26 cm;-0.13 cm), but no association was found for men. CONCLUSIONS Overall, no strong relationship between whole grain intake, measured from questionnaires or using biomarkers was found in relation to changes in body weight and WC.
Collapse
Affiliation(s)
- C Kyrø
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
- Nutrition and Metabolism Section, International Agency for Research on Cancer (WHO-IARC), Lyon, France
| | - M Kristensen
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - M U Jakobsen
- Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark
| | - J Halkjær
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - R Landberg
- Department of Food Science, BioCenter, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Hb As Bueno-de-Mesquita
- Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment, Bilthoven, The Netherlands
- Department of Gastroenterology, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - J Christensen
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - I Romieu
- Nutrition and Metabolism Section, International Agency for Research on Cancer (WHO-IARC), Lyon, France
| | - A Tjønneland
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - A Olsen
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| |
Collapse
|
40
|
Eriksen AK, Kyrø C, Nørskov N, Bolvig AK, Christensen J, Tjønneland A, Overvad K, Landberg R, Olsen A. Prediagnostic enterolactone concentrations and mortality among Danish men diagnosed with prostate cancer. Eur J Clin Nutr 2017; 71:1235-1240. [PMID: 28378849 DOI: 10.1038/ejcn.2017.42] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 11/03/2016] [Accepted: 02/28/2017] [Indexed: 11/09/2022]
Abstract
BACKGROUND/OBJECTIVES Evidence on the role of diet in relation to prostate cancer progression is sparse. Foods rich in lignans have shown beneficial effects on prostate cancer progression in both animal studies and small human intervention studies, including beneficial effects on prostate-specific antigen levels and tumour growth. The lignan metabolite, enterolactone, has further shown to slow prostate cancer cell growth in vitro. The aim was to investigate the association between prediagnostic enterolactone concentrations and mortality among men with prostate cancer.Subljects/Methods:Prediagnostic plasma concentrations of enterolactone from 1390 men diagnosed with prostate cancer from the Danish Diet, Cancer and Health cohort were related to all-cause or prostate cancer-specific death, using Cox proportional hazards models with follow-up time (from the date of diagnose until the date of death, emigration or end of follow-up by December 2013) as the underlying time axis. RESULTS The hazard ratios for enterolactone concentrations assessed linearly by 20 nmol/l increments was 0.95 (0.90, 1.02) for all-cause mortality and 0.98 (0.92, 1.05) for prostate cancer-specific mortality. Categorisation of enterolactone concentrations into quartiles did not reveal a different pattern. No effect modifications by smoking, body mass index or sport were observed, and the associations did not differ by prostate cancer aggressiveness. CONCLUSIONS We found no association between enterolactone concentrations and mortality among men diagnosed with prostate cancer.
Collapse
Affiliation(s)
- A K Eriksen
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - C Kyrø
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - N Nørskov
- Department of Animal Science, Aarhus University, Tjele, Denmark
| | - A K Bolvig
- Department of Animal Science, Aarhus University, Tjele, Denmark
| | - J Christensen
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - A Tjønneland
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| | - K Overvad
- Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus C, Denmark
| | - R Landberg
- Department of Molecular Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.,Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
| | - A Olsen
- Unit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
| |
Collapse
|
41
|
Fachmann MSR, Löfström C, Hoorfar J, Hansen F, Christensen J, Mansdal S, Josefsen MH. Detection of Salmonella enterica in Meat in Less than 5 Hours by a Low-Cost and Noncomplex Sample Preparation Method. Appl Environ Microbiol 2017; 83:e03151-16. [PMID: 27986726 PMCID: PMC5311390 DOI: 10.1128/aem.03151-16] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Accepted: 12/13/2016] [Indexed: 11/20/2022] Open
Abstract
Salmonella is recognized as one of the most important foodborne bacteria and has wide health and socioeconomic impacts worldwide. Fresh pork meat is one of the main sources of Salmonella, and efficient and fast methods for detection are therefore necessary. Current methods for Salmonella detection in fresh meat usually include >16 h of culture enrichment, in a few cases <12 h, thus requiring at least two working shifts. Here, we report a rapid (<5 h) and high-throughput method for screening of Salmonella in samples from fresh pork meat, consisting of a 3-h enrichment in standard buffered peptone water and a real-time PCR-compatible sample preparation method based on filtration, centrifugation, and enzymatic digestion, followed by fast-cycling real-time PCR detection. The method was validated in an unpaired comparative study against the Nordic Committee on Food Analysis (NMKL) reference culture method 187. Pork meat samples (n = 140) were either artificially contaminated with Salmonella at 0, 1 to 10, or 10 to 100 CFU/25 g of meat or naturally contaminated. Cohen's kappa for the degree of agreement between the rapid method and the reference was 0.64, and the relative accuracy, sensitivity, and specificity for the rapid method were 81.4, 95.1, and 97.9%, respectively. The 50% limit of detections (LOD50s) were 8.8 CFU/25 g for the rapid method and 7.7 CFU/25 g for the reference method. Implementation of this method will enable faster release of Salmonella low-risk meat, providing savings for meat producers, and it will help contribute to improved food safety.IMPORTANCE While the cost of analysis and hands-on time of the presented rapid method were comparable to those of reference culture methods, the fast product release by this method can provide the meat industry with a competitive advantage. Not only will the abattoirs save costs for work hours and cold storage, but consumers and retailers will also benefit from fresher meat with a longer shelf life. Furthermore, the presented sample preparation might be adjusted for application in the detection of other pathogenic bacteria in different sample types.
Collapse
Affiliation(s)
- M S R Fachmann
- National Food Institute, Technical University of Denmark, Søborg, Denmark
| | - C Löfström
- National Food Institute, Technical University of Denmark, Søborg, Denmark
| | - J Hoorfar
- National Food Institute, Technical University of Denmark, Søborg, Denmark
| | - F Hansen
- Danish Technological Institute, DMRI, Taastrup, Denmark
| | - J Christensen
- National Food Institute, Technical University of Denmark, Søborg, Denmark
| | - S Mansdal
- Danish Technological Institute, DMRI, Taastrup, Denmark
| | - M H Josefsen
- National Food Institute, Technical University of Denmark, Søborg, Denmark
| |
Collapse
|
42
|
Mushet DM, Christensen J, Bennett M, Alexander LC. Biota: Providing often-overlooked connections among freshwater systems. Water Resour Impact 2017; 19:11-13. [PMID: 36959972 PMCID: PMC10032040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 03/25/2023]
Abstract
When we think about connections in and among aquatic systems, we typically envision clear headwater streams flowing into downstream rivers, river floodwaters spilling out onto adjacent floodplains, or groundwater connecting wetlands to lakes and streams. However, there is another layer of connectivity moving materials among freshwater systems, one with connections that are not always tied to down-gradient flows of surface waters and groundwater. These movements are those of organisms, key components of virtually every freshwater system on the planet. In their movements across the landscape, biota connect aquatic systems in often-overlooked ways.
Collapse
Affiliation(s)
- D M Mushet
- U.S. Geological Survey Northern Prairie Wildlife Research Center
| | | | - M Bennett
- U.S. Environmental Protection Agency
| | | |
Collapse
|
43
|
Werner T, Heist R, Carvajal R, Adkins D, Alva A, Goel S, Hong D, Bazhenova L, Saleh M, Siegel R, Kyriakopoulos C, Blakely C, Eaton K, Lauer R, Wang D, Schwartz G, Neuteboom S, Potvin D, Faltaos D, Chen I, Christensen J, Levisetti M, Chao R, Bauer T. P2.06-001 A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1494] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
44
|
Nemunaitis J, Borghaei H, Akerley W, Gadgeel S, Spira A, Rybkin I, Faltaos D, Chen I, Christensen J, Potvin D, Velastegui K, Levisetti M, Husain H. P2.06-014 Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1507] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 2016; 1:e87062. [PMID: 27882345 DOI: 10.1172/jci.insight.87062] [Citation(s) in RCA: 326] [Impact Index Per Article: 40.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND. Comprehensive genomic profiling of a patient's cancer can be used to diagnose, monitor, and recommend treatment. Clinical implementation of tumor profiling in an enterprise-wide, unselected cancer patient population has yet to be reported. METHODS. We deployed a hybrid-capture and massively parallel sequencing assay (OncoPanel) for all adult and pediatric patients at our combined cancer centers. Results were categorized by pathologists based on actionability. We report the results for the first 3,727 patients tested. RESULTS. Our cohort consists of cancer patients unrestricted by disease site or stage. Across all consented patients, half had sufficient and available (>20% tumor) material for profiling; once specimens were received in the laboratory for pathology review, 73% were scored as adequate for genomic testing. When sufficient DNA was obtained, OncoPanel yielded a result in 96% of cases. 73% of patients harbored an actionable or informative alteration; only 19% of these represented a current standard of care for therapeutic stratification. The findings recapitulate those of previous studies of common cancers but also identify alterations, including in AXL and EGFR, associated with response to targeted therapies. In rare cancers, potentially actionable alterations suggest the utility of a "cancer-agnostic" approach in genomic profiling. Retrospective analyses uncovered contextual genomic features that may inform therapeutic response and examples where diagnoses revised by genomic profiling markedly changed clinical management. CONCLUSIONS. Broad sequencing-based testing deployed across an unselected cancer cohort is feasible. Genomic results may alter management in diverse scenarios; however, additional barriers must be overcome to enable precision cancer medicine on a large scale. FUNDING. This work was supported by DFCI, BWH, and the National Cancer Institute (5R33CA155554 and 5K23CA157631).
Collapse
Affiliation(s)
- Lynette M Sholl
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Khanh Do
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Early Drug Discovery Center
| | - Priyanka Shivdasani
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Ethan Cerami
- Department of Biostatistics and Computational Biology, and
| | - Adrian M Dubuc
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Frank C Kuo
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Elizabeth P Garcia
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Yonghui Jia
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Phani Davineni
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Ryan P Abo
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Center for Cancer Genome Discovery, DFCI, Boston, Massachusetts, USA
| | - Trevor J Pugh
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Ontario, Canada
| | | | - Aaron R Thorner
- Center for Cancer Genome Discovery, DFCI, Boston, Massachusetts, USA
| | - Matthew Ducar
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Center for Cancer Genome Discovery, DFCI, Boston, Massachusetts, USA
| | - Alice H Berger
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
| | - Mizuki Nishino
- Department of Radiology, DFCI and Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Katherine A Janeway
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA
| | - Alanna Church
- Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Marian Harris
- Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Lauren L Ritterhouse
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Joshua D Campbell
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Vanesa Rojas-Rudilla
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Azra H Ligon
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Shakti Ramkissoon
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - James M Cleary
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Early Drug Discovery Center
| | - Ursula Matulonis
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Geoffrey R Oxnard
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | | | | | | | - William C Hahn
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Center for Cancer Genome Discovery, DFCI, Boston, Massachusetts, USA.,Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.,Lank Center for Genitourinary Oncology and
| | | | - David J Kwiatkowski
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Bruce E Johnson
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Matthew Meyerson
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Center for Cancer Genome Discovery, DFCI, Boston, Massachusetts, USA.,Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
| | - Levi A Garraway
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.,Center for Cancer Precision Medicine, DFCI, Boston, Massachusetts, USA
| | - Geoffrey I Shapiro
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Early Drug Discovery Center
| | - Barrett J Rollins
- Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Neal I Lindeman
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Laura E MacConaill
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Center for Cancer Genome Discovery, DFCI, Boston, Massachusetts, USA
| |
Collapse
|
46
|
Hansen L, Ratnam J, Thorup H, Christensen J, Ringby B. Exercise addiction – a qualitative study about experience and everyday-life of exercise addicts. Physiotherapy 2016. [DOI: 10.1016/j.physio.2016.10.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
47
|
Soteres D, Jacobson K, Moldovan D, Christensen J, Van Leerberghe A, Wang Y, Schranz J, Aygören-Pürsün E, Martinez-Saguer I. P088 Pharmacokinetics/pharmacodynamics of C1 inhibitor for prevention of angioedema attacks in children with hereditary angioedema (HAE). Ann Allergy Asthma Immunol 2016. [DOI: 10.1016/j.anai.2016.09.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
48
|
Bazhenova L, Mehra R, Nagy T, Cavanna L, Lee JS, Han JY, Kim H, Halmos B, Shum M, Schreeder M, Rybkin I, Badin F, Mena R, Jänne P, Christensen J, Tassell V, Chao R, Faltaos D, Kim DW. Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.93] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Larsen S, Brasso K, Christensen J, Johansen C, Tjønneland A, Friis S, Iversen P, Dalton S. Socioeconomic position and mortality among patients with prostate cancer: influence of mediating factors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw387.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Abstract
Swelling of the submandibular, sublingual and/or parotid glands (“iodide mumps”) is an uncommon complication to intravascular administration of contrast material. The etiology remains unclear, but the reaction seems to be idiosyncratic or related to toxic accumulation of iodide in the ductal systems of the salivary glands. The introduction of nonionic contrast media has not eliminated the risk of developing iodide mumps. The first reported case of iodide mumps after intravascular administration of iopromide (Ultravist 300) is presented.
Collapse
|